Candel Therapeutics, Inc. 8K

Candel Therapeutics furnished an investor presentation reporting positive late‑stage clinical data and commercialization plans for its lead programs, especially aglatimagene in prostate cancer with an expected BLA filing in Q4 2026.

Candel Therapeutics, Inc. (NASDAQ: CADL) furnished a September 2026 corporate presentation (Exhibit 99.1) outlining clinical and commercial progress for its oncolytic and gene therapy programs, highlighting positive Phase 3 results for aglatimagene besadenovec (CAN‑2409) in intermediate‑ to high‑risk localized prostate cancer with statistically significant improvements in disease‑free survival and prostate cancer–specific disease‑free survival, favorable safety data, and plans to submit a BLA in Q4 2026, as well as encouraging overall survival and biomarker data from a Phase 2a trial of aglatimagene in NSCLC patients with inadequate response to immune checkpoint inhibitors and survival data from early‑stage trials of linoserpaturev (CAN‑3110) in recurrent high‑grade glioma, together with financing arrangements, cash runway into Q1 2028, and pre‑commercialization activities for a potential launch of aglatimagene.

Filing Facts

CIK

1841387

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-386561

Alert Tier

6